191 related articles for article (PubMed ID: 20737201)
1. Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.
Chiusolo P; Metafuni E; Cattani P; Piccirillo N; Santangelo R; Manzara S; Bellesi S; De Michele T; Leone G; Sica S
J Clin Immunol; 2010 Nov; 30(6):894-902. PubMed ID: 20737201
[TBL] [Abstract][Full Text] [Related]
2. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
Reddy N; Rezvani K; Barrett AJ; Savani BN
Biol Blood Marrow Transplant; 2011 May; 17(5):591-7. PubMed ID: 20732435
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
[TBL] [Abstract][Full Text] [Related]
5. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
8. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
9. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum.
Aalto SM; Juvonen E; Tarkkanen J; Volin L; Ruutu T; Mattila PS; Piiparinen H; Knuutila S; Hedman K
J Clin Virol; 2003 Dec; 28(3):275-83. PubMed ID: 14522066
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
12. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.
Han SB; Bae EY; Lee JW; Jang PS; Lee DG; Chung NG; Jeong DC; Cho B; Lee SJ; Kang JH; Kim HK
Int J Hematol; 2014 Aug; 100(2):188-99. PubMed ID: 24981711
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract][Full Text] [Related]
14. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
[No Abstract] [Full Text] [Related]
15. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease.
Rosselet A; Vu DH; Meylan P; Chaubert AS; Schapira M; Pascual M; Aubert V; Tissot JD; Duchosal MA
Clin Transplant; 2009; 23(1):74-82. PubMed ID: 19200218
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
17. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
[TBL] [Abstract][Full Text] [Related]
19. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.
Mehra V; Rhone E; Widya S; Zuckerman M; Potter V; Raj K; Kulasekararaj A; McLornan D; de Lavallade H; Benson-Quarm N; Lim C; Ware S; Sudhanva M; Malik O; Nicholas R; Muraro PA; Marsh J; Mufti GJ; Silber E; Pagliuca A; Kazmi MA
Clin Infect Dis; 2019 Oct; 69(10):1757-1763. PubMed ID: 30980715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
